{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"80.4","value":"173.4"},{"groupId":"OG001","spread":"73.7","value":"325.8"}]}],"title":"Part B: Maximum Plasma Concentration (Cmax) of DZD9008"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"113.4","value":"18.90"},{"groupId":"OG001","spread":"78.2","value":"40.40"}]}],"title":"Part B: Maximum Plasma Concentration (Cmax) of DZ0753"}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"21"}],"units":"Participants"}],"description":"Maximum observed plasma concentration, obtained directly from the observed concentration versus time data. Calculated for the single dose.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Patients with EGFR exon20ins, previously treated with at least one line of systemic therapy.\n\nPatients were randomized at a 1:1 ratio to receive sunvozertinib 200 mg once daily continuously.","id":"OG000","title":"Part B Dose Extension Cohort 1: EGFR exon20ins, Previously Treated; Sunvozertinib 200 mg"},{"description":"Patients with EGFR exon20ins, previously treated with at least one line of systemic therapy.\n\nPatients were randomized at a 1:1 ratio to receive sunvozertinib 300 mg once daily continuously.","id":"OG001","title":"Part B Dose Extension Cohort 2: EGFR exon20ins, Previously Treated; Sunvozertinib 300 mg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All dosed participants who have at least one measurable plasma concentration of DZD9008 post dose with no protocol deviations or adverse event thought to impact the analysis of the PK data.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1: 0 (predose) up to 24 hours","title":"Part B: Maximum Plasma Concentration (Cmax) of DZD9008 and DZ0753","type":"SECONDARY","unitOfMeasure":"ng/mL"}